Immuron Limited (IMC.AX)
AUD 0.08
(-3.7%)
AUD 0.08
(-3.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 4.9 Million AUD | 171.67% |
| 2023 | 1.8 Million AUD | 135.85% |
| 2022 | 765.19 Thousand AUD | 424.91% |
| 2021 | 145.77 Thousand AUD | -94.21% |
| 2020 | 2.51 Million AUD | 5.49% |
| 2019 | 2.38 Million AUD | 29.55% |
| 2018 | 1.84 Million AUD | 31.99% |
| 2017 | 1.39 Million AUD | 39.47% |
| 2016 | 1 Million AUD | -0.13% |
| 2015 | 1 Million AUD | 2.17% |
| 2014 | 981.05 Thousand AUD | 555.1% |
| 2013 | 149.75 Thousand AUD | -66.65% |
| 2012 | 449.01 Thousand AUD | 109.87% |
| 2011 | 213.95 Thousand AUD | -53.68% |
| 2010 | 461.89 Thousand AUD | -11.87% |
| 2009 | 524.1 Thousand AUD | 78.93% |
| 2008 | 292.9 Thousand AUD | -93.11% |
| 2007 | 4.24 Million AUD | 6.17% |
| 2006 | 4 Million AUD | -17.78% |
| 2005 | 4.86 Million AUD | 32.36% |
| 2004 | 3.67 Million AUD | 0.0% |
| 2003 | - AUD | -100.0% |
| 2002 | 1.98 Million AUD | 305.9% |
| 2001 | 488.23 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 4.9 Million AUD | 171.67% |
| 2024 Q2 | 2.35 Million AUD | 0.0% |
| 2024 Q4 | 2.54 Million AUD | 0.0% |
| 2023 FY | 1.8 Million AUD | 135.85% |
| 2023 Q2 | 583.64 Thousand AUD | 0.0% |
| 2023 Q4 | 1.22 Million AUD | 0.0% |
| 2022 Q4 | 534.22 Thousand AUD | 0.0% |
| 2022 Q2 | 230.96 Thousand AUD | 0.0% |
| 2022 FY | 765.19 Thousand AUD | 424.91% |
| 2021 Q2 | 20.3 Thousand AUD | 0.0% |
| 2021 FY | 145.77 Thousand AUD | -94.21% |
| 2021 Q4 | 125.46 Thousand AUD | 0.0% |
| 2020 Q2 | 1.55 Million AUD | 0.0% |
| 2020 FY | 2.51 Million AUD | 5.49% |
| 2020 Q4 | 961.94 Thousand AUD | 0.0% |
| 2019 FY | 2.38 Million AUD | 29.55% |
| 2019 Q4 | 1.4 Million AUD | 0.0% |
| 2019 Q2 | 978.23 Thousand AUD | 0.0% |
| 2018 Q4 | 923.77 Thousand AUD | 0.0% |
| 2018 Q2 | 919.13 Thousand AUD | 0.0% |
| 2018 FY | 1.84 Million AUD | 31.99% |
| 2017 Q4 | 693.09 Thousand AUD | 0.0% |
| 2017 FY | 1.39 Million AUD | 39.47% |
| 2017 Q2 | 703.09 Thousand AUD | 0.0% |
| 2016 Q4 | 503.85 Thousand AUD | 0.0% |
| 2016 Q2 | 497.22 Thousand AUD | 0.0% |
| 2016 FY | 1 Million AUD | -0.13% |
| 2015 Q4 | 473.12 Thousand AUD | 0.0% |
| 2015 Q2 | 529.25 Thousand AUD | 0.0% |
| 2015 FY | 1 Million AUD | 2.17% |
| 2014 Q2 | 379.61 Thousand AUD | 0.0% |
| 2014 FY | 981.05 Thousand AUD | 555.1% |
| 2014 Q4 | 664.52 Thousand AUD | 0.0% |
| 2013 Q3 | 37.43 Thousand AUD | -76.67% |
| 2013 FY | 149.75 Thousand AUD | -66.65% |
| 2013 Q1 | 112.25 Thousand AUD | 0.0% |
| 2013 Q4 | -10.73 Thousand AUD | -128.67% |
| 2013 Q2 | 160.48 Thousand AUD | 42.97% |
| 2012 Q1 | 53.48 Thousand AUD | 0.0% |
| 2012 FY | 449.01 Thousand AUD | 109.87% |
| 2012 Q4 | 112.25 Thousand AUD | 0.0% |
| 2012 Q3 | 112.25 Thousand AUD | 0.0% |
| 2012 Q2 | 112.25 Thousand AUD | 109.87% |
| 2011 Q3 | 53.48 Thousand AUD | 0.0% |
| 2011 Q4 | 53.48 Thousand AUD | 0.0% |
| 2011 FY | 213.95 Thousand AUD | -53.68% |
| 2011 Q2 | 53.48 Thousand AUD | -53.68% |
| 2011 Q1 | 115.47 Thousand AUD | 0.0% |
| 2010 Q3 | 115.47 Thousand AUD | 0.0% |
| 2010 FY | 461.89 Thousand AUD | -11.87% |
| 2010 Q4 | 115.47 Thousand AUD | 0.0% |
| 2010 Q2 | 115.47 Thousand AUD | -11.87% |
| 2010 Q1 | 131.02 Thousand AUD | 0.0% |
| 2009 FY | 524.1 Thousand AUD | 78.93% |
| 2009 Q1 | 73.22 Thousand AUD | 0.0% |
| 2009 Q2 | 131.02 Thousand AUD | 78.93% |
| 2009 Q3 | 131.02 Thousand AUD | 0.0% |
| 2009 Q4 | 131.02 Thousand AUD | 0.0% |
| 2008 Q1 | 1.06 Million AUD | 0.0% |
| 2008 Q2 | 73.22 Thousand AUD | -93.11% |
| 2008 FY | 292.9 Thousand AUD | -93.11% |
| 2008 Q4 | 73.22 Thousand AUD | 0.0% |
| 2008 Q3 | 73.22 Thousand AUD | 0.0% |
| 2007 Q1 | 1 Million AUD | 0.0% |
| 2007 FY | 4.24 Million AUD | 6.17% |
| 2007 Q2 | 1.06 Million AUD | 6.17% |
| 2007 Q4 | 1.06 Million AUD | 0.0% |
| 2007 Q3 | 1.06 Million AUD | 0.0% |
| 2006 Q2 | 1 Million AUD | -17.78% |
| 2006 Q1 | 1.21 Million AUD | 0.0% |
| 2006 Q4 | 1 Million AUD | 0.0% |
| 2006 Q3 | 1 Million AUD | 0.0% |
| 2006 FY | 4 Million AUD | -17.78% |
| 2005 Q2 | 1.21 Million AUD | 32.36% |
| 2005 FY | 4.86 Million AUD | 32.36% |
| 2005 Q4 | 1.21 Million AUD | 0.0% |
| 2005 Q3 | 1.21 Million AUD | 0.0% |
| 2005 Q1 | 919.38 Thousand AUD | 0.0% |
| 2004 FY | 3.67 Million AUD | 0.0% |
| 2004 Q2 | 919.38 Thousand AUD | 0.0% |
| 2004 Q3 | 919.38 Thousand AUD | 0.0% |
| 2004 Q4 | 919.38 Thousand AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2003 Q1 | 495.43 Thousand AUD | 0.0% |
| 2003 Q2 | - AUD | -100.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | -100.0% |
| 2002 Q1 | 122.05 Thousand AUD | 0.0% |
| 2002 Q4 | 495.43 Thousand AUD | 0.0% |
| 2002 Q3 | 495.43 Thousand AUD | 0.0% |
| 2002 Q2 | 495.43 Thousand AUD | 305.9% |
| 2002 FY | 1.98 Million AUD | 305.9% |
| 2001 Q3 | 122.05 Thousand AUD | 0.0% |
| 2001 Q4 | 122.05 Thousand AUD | 0.0% |
| 2001 Q2 | 122.05 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | 488.23 Thousand AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 92.621% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -5063.519% |
| Biome Australia Limited | 13 Million AUD | 62.311% |
| Patrys Limited | 1.39 Million AUD | -251.671% |
| Orthocell Limited | 5.31 Million AUD | 7.761% |
| Imugene Limited | - AUD | -Infinity% |
| Noxopharm Limited | 2.4 Million AUD | -104.263% |
| PYC Therapeutics Limited | 22.05 Million AUD | 77.774% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 34.257% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -32.069% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -449.56% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -111.728% |
| CSL Limited | 22.41 Billion AUD | 99.978% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -28740.382% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -26662.364% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 94.44% |
| Starpharma Holdings Limited | 8.28 Million AUD | 40.851% |
| Nanollose Limited | 12.5 Thousand AUD | -39119.782% |
| Memphasys Limited | 60 Thousand AUD | -8071.442% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -304.441% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -10.109% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -714.673% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -291.736% |
| Race Oncology Limited | 4 Million AUD | -22.465% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.013% |
| Dimerix Limited | 583.47 Thousand AUD | -740.283% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | -39.853% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 57.391% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -21.984% |
| BTC Health Limited | 16.36 Thousand AUD | -29868.612% |
| Acrux Limited | 5.09 Million AUD | 3.695% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 97.886% |
| Biotron Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -3120.484% |
| AdAlta Limited | 1.73 Million AUD | -182.131% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1538.505% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -964.921% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -7351.163% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -935.34% |
| Actinogen Medical Limited | 9.93 Million AUD | 50.633% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -88.721% |